Full-Time

Manager of Billing Operations

Accounts Receivable

Posted on 9/10/2025

Caris

Caris

1,001-5,000 employees

Provides AI-powered molecular insights for cancer

No salary listed

Irving, TX, USA

In Person

Category
Accounting (2)
,
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
Requirements
  • Associate’s degree accounting, finance, healthcare administration, or a related field OR equivalent combination of education and experience
  • 3+ years of experience of Medical Billing
  • 5+ years of experience in a related industry
  • Expert in Business-to-Business (B2B) communications.
  • Advance knowledge of Medicare, Medicaid and commercial insurance guidelines, and medical billing processes
  • Proficient in insurance processing, guidelines and general policies related to all payers.
  • Proficient in clinical documentation review to align with insurance authorization requirements
  • Maintains compliance with HIPPA and other healthcare regulations
  • Advanced knowledge of CPT, ICD-10
  • Maintains patient confidentiality and complies with HIPAA regulations
  • Demonstrates solid time management skills, organization, and a strong attention to detail
  • Demonstrated leadership and interpersonal skills. Willingness to lead by example.
  • A good understanding of techniques for identifying, documenting, and testing of controls.
  • Demonstrated leadership and interpersonal skills. The role will require interaction with a wide range of fellow employees, senior leaders, as well as external auditors and experts.
  • Maintain a high standard of discipline and professionalism.
  • Ability to think creatively and initiatenew ideas or solutions to business issues.
  • Independence of thought and sound judgment relating to business needs.
  • Demonstrated commitment, self-motivation, and drive.
  • Ability to work with minimal guidance; Proactive, motivated self-starter
  • Flexibility and proven ability to handle and manage frequent changes effectively and efficiently
  • Meets productivity/performance standards as set forth by management.
  • Adheres to all company policies and procedures.
  • Possess strong interpersonal skills and the ability to sell the business reason for the change. Act as an agent of change while maintainingappropriate level of independence.
  • Ability to work in a fast past, competing deadline driven environment.
  • Strong knowledge of Microsoft Office Suite, specifically Access, Word, Excel, Outlook, Accounting Software, and general working knowledge of Internet for business use. Demonstrated ability to learn new accounting software.
Responsibilities
  • Meets all deliverables and goals set by department.
  • Meets all regulatory agency requirements as they pertain to job function.
  • Manages day-to-day activities of multiple teams of Health Information department, including management of in-bound customer correspondence, customer phone calls, and patient case discrepancy management.
  • Ensures the needs of clients, patients, field staff, and laboratory are appropriately addressed by prioritizing work of multiple as needed.
  • Works cross functionally with other department leaders to improve workflows and enhance customer satisfaction.
  • Represents the Health Information department in cross functional teams to ensure larger company projects include Health Information input.
  • Ensures service quality by monitoring team member performance, identifying performance issues and implementing corrective action as necessary.
  • Hires and trains team members.
  • Develops training programs.
  • Investigates and resolves escalated and complex client issues and problems, identifying areas of customer satisfaction and dissatisfaction.
  • Monitors employee’s performance and productivity. Utilizes processes and available tools to analyze trends, maintain and enhance performance, and report statistics. Provides regular feedback to all Health Information team members on their performance; identifies areas of improvement. Manages performance accountabilities for individual team members.
  • Collaborates with management as it relates to team member challenges dealing with performance and behavior.
  • Ensures adequate support coverage by managing adherence to work schedules fully utilizing daily management reports/tools.
  • Provides on-going training and development of team members through effective coaching, motivating and proactive career development.
  • Mentors, coaches, and addresses developmental opportunities and disciplinary issues on the team. Implements corrective action and further development plans as necessary. Uses motivational techniques to assist team members in maintaining and exceeding standards.
  • Conducts audits on work and determinesadditional training and counseling that may be required due to the results of the audit; including, providing recommendations, guidance, and implementing solutions to improve results.
  • Actively supports and engages Health Information team members in the quality process. Assesses training needs as identified, shares results in a timely manner, and provides training and coaching to drive continuous improvement.
  • Supports new technologies as a tool for driving increased efficiencies and stronger results.
  • Conducts regular team meetings. Attends applicable department/management meetings. Keeps team informed of new processes and general updates.
  • Manages correspondence, escalated issues and requirements/regulations.
  • Works collaboratively to problem solve and participate cross functionally with other teams as necessary.
  • Maintains a high level of confidentiality to protect the concerns of the company, management and employees.
  • Provides strong, consistent leadership and direction to the team, translates company and department vision into measurable goals and objectives for the team, and helps team members understand how they contribute to Caris’s success.
  • Serves as a role model for staff, maintaining a professional, positive work environment that promotes a high-performance environment.
  • Takes ownership for personal growth and career development of self. Focused on continuing to expand leadership skills, experience, and capability.
  • Accepts other duties as assigned.
Desired Qualifications
  • Bachelor’s degree accounting, finance, healthcare administration, or a related field OR equivalent combination of education and experience
  • 5+ years’ experience in a medical billing management position, with experience in AR.
  • Demonstrated career growth in previous healthcare administration, or a related field.
  • Strong training/development background.
  • Must possess professionalism, superior organizational skills, communications skills that allow the ability to educate and influence, an unrelenting passion for persistent follow up, and a drive towards problem resolution.
  • Overall responsibility will be to follow-up on all claims from billing through final resolution and reduce delinquent accounts to achieve maximum collections from all sources.
  • Drive for Results (Service, Quality, and Continuous Improvement) – Ensure procedures and processes are in place that will lead to delivery of quality results and continually reassess their effectiveness to achieve continuous improvement.
  • Communication – Proficient verbal and written communication skills. Willingness to share and receive information and ideas from all levels of the organization to achieve the desired results.
  • Teamwork – Commitment to the successful achievement of team and organizational goals through a desire to participate with and help other members of the team.
  • Customer Service Focus – Demonstrate a focus on listening to and understanding client/customer needs and then delighting the client/customer by exceeding service and quality expectations.

Caris Life Sciences provides molecular information to cancer patients, oncologists, researchers, and payors to guide personalized cancer care. Its core product uses molecular profiling and artificial intelligence to interpret a cancer’s molecular features at diagnosis, helping predict how the cancer may behave and which treatments are likely to work. The company differentiates itself by delivering a comprehensive, AI-assisted set of molecular insights across multiple stakeholders, translating complex genomic and other molecular data into actionable treatment guidance. Its goal is to improve cancer outcomes by enabling more precise, tailored therapy for each patient.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Irving, Texas

Founded

1996

Simplify Jobs

Simplify's Take

What believers are saying

  • MI Clarity launched May 5, 2026, creating a near-term breast oncology wedge.
  • Q1 2026 revenue rose 79% to $216.2 million with positive adjusted EBITDA.
  • New assays in glioblastoma, NSCLC, and myeloid cancers expand Caris’ addressable workflows.

What critics are saying

  • Foundation Medicine, Tempus, and Guardant intensify pricing and reimbursement competition.
  • MI Clarity’s narrow label limits adoption against entrenched breast cancer recurrence tests.
  • Debt financing and quarterly cash covenants pressure Caris if reimbursement or volume slows.

What makes Caris unique

  • Caris combines whole-genome, whole-exome, and whole-transcriptome profiling with AI.
  • MI Clarity analyzes routine pathology slides without requiring additional tissue or sequencing.
  • Caris leverages a proprietary multimodal clinico-genomic dataset spanning hundreds of thousands of cases.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Caris who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Health Savings Account/Flexible Spending Account

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Company Match

Employee Assistance Program

Pet Insurance

Legal Assistance

Tuition Assistance

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-2%

2 year growth

-1%
PR Newswire
Apr 8th, 2026
Caris Life Sciences launches AI-powered tool to determine chemotherapy benefit or harm for NSCLC patients

Caris Life Sciences has launched an AI-driven molecular insight to help determine which non-small cell lung cancer patients benefit from adding chemotherapy to immunotherapy treatment, and which may be harmed by it. The signature uses Whole Exome Sequencing and Whole Transcriptome Sequencing combined with clinical data. The tool targets patients with driver-negative tumours expressing high PD-L1 levels. It first stratifies patients into higher versus standard-risk groups, then predicts who may benefit from additional chemotherapy. The signature was developed using Caris' clinico-genomic datasets and machine learning to identify molecular signatures associated with treatment response. NSCLC is the most common type of lung cancer. The new AI insight aims to reduce unnecessary chemotherapy exposure whilst improving treatment outcomes through more personalised therapy decisions.

ABF Journal
Apr 6th, 2026
Caris Life Sciences secures up to $1.2B in senior credit facilities from Blue Owl and Blackstone

Caris Life Sciences has secured senior secured credit facilities totalling up to $1.2 billion from funds managed by Blue Owl Capital and Blackstone, with Blue Owl serving as administrative agent. The financing comprises a $400 million initial term loan funded at closing, a $300 million committed delayed draw term loan facility available through August 2027, and an uncommitted $500 million incremental facility. The initial term loan matures in April 2031. Interest rates are term SOFR or base rate plus an additional margin of 5.00% for term SOFR rate loans and 4.00% for base rate loans. The delayed draw facility may only be used for permitted acquisitions. The agreement includes standard covenants and requires the company to maintain minimum qualified cash of $50 million tested quarterly.

PR Newswire
Apr 2nd, 2026
Caris Life Sciences launches world's first whole genome and transcriptome tumour profiling assay for myeloid malignancies

Caris Life Sciences has launched Caris ChromoSeq, described as the world's first whole genome and whole transcriptome tumour profiling assay for myeloid malignancies. The test is designed for acute myeloid leukaemia, myelodysplastic syndromes and myeloproliferative neoplasms. The assay delivers approximately 250x read depth across the genome with 40 million transcriptome reads from bone marrow aspirate or peripheral blood samples. It consolidates multiple diagnostic tests into a single seven-day turnaround assessment, aiming to expedite treatment decisions for genetically complex myeloid cancers. The Irving, Texas-based precision medicine company positions ChromoSeq as an integrated genomic solution that simplifies the myeloid diagnostic workflow whilst providing comprehensive mutation, structural variant and chromosomal abnormality detection in a single, actionable report.

PR Newswire
Mar 26th, 2026
Caris Life Sciences adds AI brain metastases risk predictions for breast and lung cancer

Caris Life Sciences has added two AI-powered signatures to its Molecular Tumour Board Report that predict brain metastases risk in breast and lung cancer patients. The signatures bring the total number of proprietary Caris AI Insights to seven. The algorithms were trained on 12,994 non-small cell lung cancer cases and 3,371 breast cancer cases with matched survival outcomes. They generate personalised predictive scores using whole exome and whole transcriptome sequencing data, helping clinicians identify high-risk patients for proactive monitoring. The insights are powered by Caris's CodeAI platform, which contains data from over 500,000 patients tested with whole exome and whole transcriptome sequencing. The technology is available through MI Cancer Seek, which received FDA approval in November 2024 as the first simultaneous sequencing-based companion diagnostic for solid tumours.

PR Newswire
Mar 25th, 2026
Caris Life Sciences to present six oncology studies utilizing proprietary multimodal data at the AACR Annual Meeting 2026.

Caris Life Sciences to present six oncology studies utilizing proprietary multimodal data at the AACR Annual Meeting 2026. Mar 25, 2026, 08:30 ET IRVING, Texas, March 25, 2026 /PRNewswire/ - Caris Life Sciences(R)(NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the Caris Precision Oncology Alliance(R)(Caris POA(R) and collaborators from leading cancer centers, will collectively present six studies at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, California to be held April 17-22, 2026. These studies leveraged Caris' robust multimodal database, which integrates Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS), immunohistochemistry (IHC) and real world clinical data, to generate clinically meaningful insights across multiple tumor types. This research reflects Caris' commitment to advancing precision oncology through deep molecular interrogation. The studies focused on breast, prostate, lung and colorectal cancers represent a collaborative effort between Caris and leading cancer centers and institutions, underscoring the power of large-scale, real world molecular evidence to accelerate discovery and improve patient outcomes. "These studies demonstrate the transformative potential of multimodal molecular data to uncover clinically meaningful patterns that would otherwise remain hidden," said James Hamrick, MD, MPH, Chairman of the Caris POA. "By combining deep genomic profiling with real world clinical evidence, Caris and its collaborators are generating insights that can directly inform treatment decisions and accelerate the development of more effective therapies for patients." Posters Include: * Spatially resolved tumor-cell MHC class II shapes adaptive immunity and therapeutic response in triple-negative breast cancer Session: Spatial Proteomics and Transcriptomics 1 Sunday, April 19, 2026, 2:00 PM - 5:00 PM PST Poster #: 1200/1 Location: Poster section 47 * Prognostic and predictive effects of TP53 co-mutations and RET fusion partners in RET-rearranged advanced NSCLC Session: Biomarkers Predictive of Therapeutic Benefit 3 Monday, April 20, 2026, 9:00 AM - 12:00 PM PST Poster #: 2434/4 Location: Poster section 40 * AR copy number amplification and AR/KLK3 expression patterns reveal mechanisms of AR signaling inhibitor (ARSI) resistance and highlight the need for AR-directed therapeutic innovation in metastatic castration resistance prostate cancer (mCRPC) Session: Molecular Targeted Therapy Monday, April 20, 2026, 2:00 PM - 5:00 PM PST Poster #: 3910/16 Location: Poster section 47 * cBioPortal for cancer genomics Session: AACR Project GENIE: Genomic Characterization Tuesday, April 21, 2026, 9:00 AM - 12:00 PM PST Poster #: 4097/2 Location: Poster section 1 * Distinct KRAS mutation codons differentially associate with microsatellite instability in colorectal carcinoma Session: Precision Oncology and Real World Data Tuesday, April 21, 2026, 9:00 AM - 12:00 PM PST Poster #: 5336/4 Location: Poster section 46 * MCM2 and the origin licensing complex: A putative node of ER+/HER2- breast cancer therapy resistance Session: Real World Data to Provide Real World Evidence Tuesday, April 21, 2026, 2:00 PM - 5:00 PM PST Poster #: 6647/16 Location: Poster section 47 Research highlights will be available onsite at Caris' booth #1423. The full abstracts will be available on the Caris website following the presentations. About Caris Life Sciences Caris Life Sciences(R)(Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development. Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets. Forward Looking Statements This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law. Caris Life Sciences Media: Corporate Communications [email protected] 214.294.5606 SOURCE Caris Life Sciences

INACTIVE